Published: March 2026
Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that has been investigated extensively in preclinical research for its pharmacological interactions with the melanocortin receptor family. First described by researchers at the University of Arizona in the early 1990s, MT-II was developed as a conformationally constrained, metabolically stable probe to study the melanocortin system at higher resolution than the endogenous ligands allow. Its cyclized backbone and incorporation of a D-phenylalanine residue confer resistance to enzymatic degradation and substantially increased binding affinity relative to linear α-MSH, making it a widely used tool compound for in vitro receptor pharmacology and in vivo animal model studies across multiple research disciplines.
Molecular Profile
| Property | Value |
|---|---|
| Common Name | Melanotan II (MT-II) |
| Systematic Name / Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ |
| Alternative Names | Melanotan-2, MT2 |
| CAS Number | 121062-08-6 |
| Molecular Formula | C₅₀H₆₉N₁₅O₉ |
| Molecular Weight | 1024.18 g/mol |
| Cyclization | Lactam bridge between Asp³ and Lys⁸ side chains |
| Key Substitutions | Nle⁴ (replaces Met), D-Phe⁷ (replaces Phe) |
| Parent Peptide | α-Melanocyte-Stimulating Hormone (α-MSH) |
White Market Peptides offers research-grade Melanotan II (10 mg) at a 99%+ purity standard, third-party tested for identity and purity. View its Certificate of Analysis (PDF) ↗
The Melanocortin Receptor System

The melanocortin system comprises five G protein-coupled receptors (MC1R through MC5R), a family of endogenous peptide ligands derived from the precursor protein proopiomelanocortin (POMC), and two endogenous antagonists: Agouti Signaling Protein (ASIP) and Agouti-Related Protein (AgRP). The POMC-derived ligands include α-, β-, and γ-MSH and adrenocorticotropin (ACTH), all of which share the conserved His-Phe-Arg-Trp tetrapeptide core responsible for receptor activation. Each of the five receptor subtypes exhibits a distinct tissue expression profile and functional specialization: MC1R is predominantly expressed on melanocytes and immune cells; MC2R is the cognate ACTH receptor in adrenal cortex; MC3R is expressed centrally (hypothalamus, limbic structures) and peripherally; MC4R is highly expressed in the central nervous system, particularly the hypothalamus and brainstem; and MC5R is found in exocrine glands and peripheral tissues. MT-II binds all five receptor subtypes with high affinity and has been used as a broad-spectrum pharmacological tool to probe pan-melanocortin receptor biology in preclinical systems, while more selective analogs have been developed to interrogate individual receptor contributions.
Hadley and Dorr (2006) reviewed the development of superpotent MSH analogs including MT-II, describing how the cyclic lactam constraint locks the peptide in a bioactive conformation that mimics the beta-turn structure of the His-D-Phe-Arg-Trp pharmacophore. Comparative binding studies have shown that MT-II displays approximately 10- to 100-fold higher potency than linear α-MSH at multiple receptor subtypes, and its metabolic half-life in plasma is substantially prolonged relative to the native ligand. PMID: 16760008
Melanocortin-1 Receptor and Pigmentation Pathway Research
The most thoroughly characterized role of the melanocortin system at the molecular level involves MC1R-mediated regulation of melanogenesis. Upon agonist binding, MC1R couples to Gαs and activates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB. Phospho-CREB drives transcriptional upregulation of Microphthalmia-associated Transcription Factor (MITF), a master regulator of the melanogenic gene program. MITF in turn induces expression of tyrosinase, tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT/TYRP2), the enzymatic machinery responsible for the conversion of tyrosine through the melanin biosynthetic cascade.
MT-II has been used as a pharmacological tool in this pathway because of its ability to engage MC1R at concentrations well below those required for endogenous α-MSH. In vitro studies in B16-F10 murine melanoma cells and primary human melanocyte cultures have used MT-II to dissect cAMP kinetics, MITF phosphorylation dynamics, and eumelanin versus phaeomelanin switching in response to MC1R activation. Haskell-Luevano and Monck (2001) reviewed structure-activity relationships across the melanocortin system and described how cyclic analogs including MT-II provided the foundational pharmacological tools for mapping the receptor binding pocket and understanding which residues of the core tetrapeptide are contact points versus conformational determinants. PMID: 11726160
Energy Homeostasis and MC3R/MC4R Research
Substantial preclinical literature has investigated the role of the central melanocortin system, particularly MC3R and MC4R, in the regulation of energy balance, feeding behavior, and metabolic signaling in rodent models. Both receptor subtypes are expressed in hypothalamic nuclei involved in metabolic regulation, including the arcuate, paraventricular, and ventromedial nuclei. MC4R in particular has been characterized as a critical node in the leptin-melanocortin pathway: leptin signaling in the arcuate nucleus activates POMC neurons that release α-MSH onto MC4R-expressing neurons in the paraventricular nucleus, suppressing food intake and increasing energy expenditure.
Fan et al. (1997) demonstrated in a landmark study that intracerebroventricular (icv) administration of MT-II in rats produced rapid, dose-dependent reductions in food intake in fed animals and in animals that had been fasted for 24 hours. The same study showed that co-administration of the melanocortin antagonist SHU9119 reversed MT-II-induced hypophagia, confirming receptor-mediated specificity. These animal model data established MT-II as one of the primary tool compounds for interrogating CNS melanocortin tone in metabolic research. PMID: 9048949
Greenfield et al. (2009) reviewed the broader evidence base for melanocortin receptor involvement in elevated BMI and energy homeostasis, noting that MC4R knockout mice develop severe early-onset elevated BMI with hyperphagia and reduced energy expenditure, and that MT-II and similar agonists have been used to pharmacologically rescue aspects of this phenotype in animal models, providing mechanistic evidence for MC4R’s role in the elevated BMI susceptibility pathway. PMID: 19183826
CNS Distribution and Central Melanocortin Circuitry
The central melanocortin system extends well beyond hypothalamic feeding circuits. MC4R expression has been documented in cortical regions, the amygdala, hippocampus, periaqueductal gray, nucleus tractus solitarius, and spinal cord dorsal horn. MC3R is expressed in the hypothalamus and limbic forebrain, and preclinical in situ hybridization and immunohistochemical mapping studies have used MC3R/MC4R agonists including MT-II to identify functional circuits regulated by melanocortin tone in behavioral neuroscience research contexts.
Kishi et al. (2003) performed detailed neuroanatomical mapping of MC4R-expressing neurons in the mouse brain and described the convergence of POMC and AgRP fiber innervation onto MC4R-positive cell populations across multiple brain regions, establishing the anatomical substrate for diverse central melanocortin effects observed in pharmacological studies employing MT-II. The broad CNS expression pattern of MC4R accounts for the range of physiological parameters observed to be sensitive to melanocortin system manipulation in animal research. PMID: 12717680
Comparison to Endogenous α-MSH: Binding and Selectivity Studies
Endogenous α-MSH is a 13-amino acid linear peptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) that binds all five melanocortin receptors but is rapidly degraded in biological fluids by prolyl endopeptidase and other proteases, resulting in a plasma half-life of minutes. MT-II was engineered to overcome this liability through two structural modifications: (1) replacement of methionine at position 4 with norleucine (Nle), eliminating the oxidation-prone thioether side chain; and (2) cyclization via a lactam bridge between the aspartate at position 3 and the lysine at position 8, constraining the backbone and reducing susceptibility to endo- and exopeptidase cleavage.
Sawyer et al. (1982), in one of the foundational papers describing the rational design of superpotent MSH analogs, demonstrated that cyclic lactam analogs incorporating D-amino acids at the Phe⁷ position produced dramatic increases in receptor potency and biological duration in frog skin bioassays, the classical model for melanocortin-induced melanophore dispersion. Competitive radioligand binding studies subsequently confirmed that MT-II displays low-nanomolar Ki values at MC1R, MC3R, MC4R, and MC5R, with modest selectivity differences across subtypes that have been exploited in structure-activity relationship studies to map receptor contact residues. PMID: 6810036
Chhajlani and Wikberg (1992) reported the cloning and expression of the human melanocortin receptor that would be designated MC1R, establishing the molecular identity of the receptor mediating melanogenic responses and providing the foundation for heterologous cell expression systems used in subsequent competitive binding and functional cAMP assays with MT-II and related analogs. PMID: 1336460
Looking to source this compound? Melanotan II (10 mg) is available for laboratory research, with documented batch testing. View its Certificate of Analysis (PDF) ↗
MC5R and Exocrine Function Research
MC5R, the least-studied melanocortin receptor subtype at the time of MT-II’s development, is expressed in exocrine glands including lacrimal, harderian, preputial, and sebaceous glands, as well as in immune cells. Chen et al. (1997) generated MC5R-deficient mice and reported that homozygous knockout animals exhibited severely reduced secretion from multiple exocrine glands and decreased production of pheromonal compounds from preputial glands, establishing a role for melanocortin signaling in exocrine secretory function. MT-II’s high-affinity binding to MC5R, an activity not shared by all melanocortin analogs, has made it a useful tool for distinguishing MC5R-mediated components of compound melanocortin receptor responses in mixed-tissue preparations. PMID: 9103201
Key Published References
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921–930. PMID: 16760008
- Haskell-Luevano C, Monck EK. Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor. Regul Pept. 2001;99(1):1–7. PMID: 11726160
- Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti elevated BMI syndrome. Nature. 1997;385(6612):165–168. PMID: 9048949
- Greenfield JR, Miller JW, Keogh JM, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med. 2009;360(1):44–52. PMID: 19183826
- Kishi T, Aschkenasi CJ, Lee CE, Mountjoy KG, Saper CB, Elmquist JK. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J Comp Neurol. 2003;457(3):213–235. PMID: 12717680
- Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA. 1980;77(10):5754–5758. PMID: 6810036
- Chhajlani V, Wikberg JE. Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA. FEBS Lett. 1992;309(3):417–420. PMID: 1336460
- Chen W, Kelly MA, Opitz-Araya X, Thomas RE, Low MJ, Cone RD. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell. 1997;91(6):789–798. PMID: 9103201
Product Availability
Melanotan II is available for qualified research applications through White Market Peptides: Melanotan II: Research Grade.
Available for Research
Melanotan II (10 mg)
99%+ purity · COA included · USA shipping